CL2015001802A1 - Compuestos derivados de quinolonas; composicion farmaceutica; y uso para el tratamiento de enfermedaddes mediadas por la inhibicion de hif polilhidrolasa, tal como infarto al miocardio, accidente cerebrovascular, anemia, entre otros - Google Patents
Compuestos derivados de quinolonas; composicion farmaceutica; y uso para el tratamiento de enfermedaddes mediadas por la inhibicion de hif polilhidrolasa, tal como infarto al miocardio, accidente cerebrovascular, anemia, entre otrosInfo
- Publication number
- CL2015001802A1 CL2015001802A1 CL2015001802A CL2015001802A CL2015001802A1 CL 2015001802 A1 CL2015001802 A1 CL 2015001802A1 CL 2015001802 A CL2015001802 A CL 2015001802A CL 2015001802 A CL2015001802 A CL 2015001802A CL 2015001802 A1 CL2015001802 A1 CL 2015001802A1
- Authority
- CL
- Chile
- Prior art keywords
- polyhydrolase
- hif
- quinolones
- anemia
- inhibition
- Prior art date
Links
- 208000006011 Stroke Diseases 0.000 title 1
- 208000007502 anemia Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 208000010125 myocardial infarction Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000007660 quinolones Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3600MU2012 | 2012-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015001802A1 true CL2015001802A1 (es) | 2015-10-02 |
Family
ID=54148255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015001802A CL2015001802A1 (es) | 2012-12-24 | 2015-06-22 | Compuestos derivados de quinolonas; composicion farmaceutica; y uso para el tratamiento de enfermedaddes mediadas por la inhibicion de hif polilhidrolasa, tal como infarto al miocardio, accidente cerebrovascular, anemia, entre otros |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9394300B2 (enExample) |
| EP (1) | EP2935221B1 (enExample) |
| JP (1) | JP6026013B2 (enExample) |
| KR (1) | KR101733901B1 (enExample) |
| CN (1) | CN104903295B (enExample) |
| AP (1) | AP2015008502A0 (enExample) |
| AR (1) | AR094300A1 (enExample) |
| AU (1) | AU2013368843B2 (enExample) |
| BR (1) | BR112015014222B1 (enExample) |
| CA (1) | CA2894636C (enExample) |
| CL (1) | CL2015001802A1 (enExample) |
| EA (1) | EA028402B1 (enExample) |
| ES (1) | ES2660288T3 (enExample) |
| IL (1) | IL239109B (enExample) |
| JO (1) | JO3781B1 (enExample) |
| MA (1) | MA38138A1 (enExample) |
| MX (1) | MX373392B (enExample) |
| MY (1) | MY175854A (enExample) |
| NZ (1) | NZ708605A (enExample) |
| PH (1) | PH12015501452B1 (enExample) |
| SG (1) | SG11201504458XA (enExample) |
| TR (1) | TR201802305T4 (enExample) |
| TW (1) | TWI598339B (enExample) |
| UA (1) | UA117122C2 (enExample) |
| WO (1) | WO2014102818A1 (enExample) |
| ZA (1) | ZA201503814B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016034108A1 (zh) * | 2014-09-02 | 2016-03-10 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其应用 |
| WO2016045125A1 (en) | 2014-09-28 | 2016-03-31 | Merck Sharp & Dohme Corp. | Inhibitors of hif prolyl hydroxylase |
| CL2015003047A1 (es) * | 2015-10-15 | 2016-06-17 | Univ Chile | Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
| CA3062972C (en) | 2017-05-09 | 2021-09-14 | Kind Pharmaceutical | Indolizine derivatives and their application in medicine |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| TW202200547A (zh) * | 2020-03-13 | 2022-01-01 | 印度商卡地拉保健有限公司 | 喹啉酮化合物的新穎鹽類 |
| EP4121009A4 (en) * | 2020-03-17 | 2024-04-17 | Zydus Lifesciences Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
| EP4138825A1 (en) | 2020-04-20 | 2023-03-01 | Akebia Therapeutics Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| EP4157233A4 (en) * | 2020-05-29 | 2024-06-26 | Zydus Lifesciences Limited | TREATMENT OF PSORIASIS AND INFLAMMATORY SKIN DISEASES |
| CN115666517A (zh) * | 2020-06-01 | 2023-01-31 | 兹杜斯生命科学有限公司 | 炎性肠病的治疗 |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| BR112023018949A2 (pt) * | 2021-03-19 | 2023-10-17 | Zydus Lifesciences Ltd | Composto, uso do mesmo para tratar anemia falciforme e composição farmacêutica compreendendo o referido composto |
| EP4308089A4 (en) * | 2021-03-19 | 2025-02-26 | Zydus Lifesciences Limited | QUINOLONE COMPOUND IN SOLID FORMS AND PROCESSES FOR THEIR PREPARATION |
| WO2022238745A1 (en) * | 2021-05-14 | 2022-11-17 | Zydus Lifesciences Limited | Topical pharmaceutical composition of hif prolyl hydroxylase inhibitors |
| TW202313072A (zh) | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | 檸檬酸鐵之兒科調配物 |
| CN113549011B (zh) * | 2021-08-10 | 2023-05-09 | 广东东阳光药业有限公司 | 德度司他的共晶或盐及其制备方法和用途 |
| WO2023042170A1 (en) * | 2021-09-20 | 2023-03-23 | Zydus Lifesciences Limited | Desidustat particles and compositions thereof |
| EP4539934A1 (en) * | 2022-06-24 | 2025-04-23 | Zydus Lifesciences Limited | Treatment for glomerular diseases |
| WO2024028744A1 (en) * | 2022-08-01 | 2024-02-08 | Zydus Lifesciences Limited | Treatment for aplastic anemia (aa) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| PL1644336T3 (pl) | 2003-06-06 | 2011-07-29 | Fibrogen Inc | Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny |
| CN101166745A (zh) * | 2005-03-02 | 2008-04-23 | 菲布罗根有限公司 | 噻吩并吡啶化合物和其使用方法 |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| JP5202327B2 (ja) | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用 |
| AR059733A1 (es) * | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| CA2647596C (en) * | 2006-04-04 | 2012-06-12 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as hif modulators |
| WO2007136990A2 (en) * | 2006-05-16 | 2007-11-29 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| EP2044068A4 (en) * | 2006-07-17 | 2010-07-21 | Merck Sharp & Dohme | 1-HYDROXY Naphthyridine Compounds as Anti- HIV Drugs |
| WO2008076425A1 (en) | 2006-12-18 | 2008-06-26 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| ES2442847T3 (es) * | 2007-04-18 | 2014-02-13 | Amgen, Inc | Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa |
| EP2136810A4 (en) * | 2007-04-18 | 2012-01-04 | Merck Sharp & Dohme | NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS |
| AU2008248234B2 (en) * | 2007-05-04 | 2011-02-03 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| AU2008248165B2 (en) * | 2007-05-04 | 2011-12-08 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
| AU2008251031B2 (en) * | 2007-05-16 | 2013-12-19 | Norman Terry Cowper | System and method for maximising solids concentration of slurry pumped through a pipeline |
| AU2008329746A1 (en) * | 2007-11-30 | 2009-06-04 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
| JP2011513222A (ja) * | 2008-02-25 | 2011-04-28 | メルク・シャープ・エンド・ドーム・コーポレイション | テトラヒドロチエノピリジン |
| JP2011513223A (ja) * | 2008-02-25 | 2011-04-28 | メルク・シャープ・エンド・ドーム・コーポレイション | テトラヒドロ−１ｈ−ピロロ縮合ピリドン |
| CN101951777A (zh) * | 2008-02-25 | 2011-01-19 | 默沙东公司 | 四氢呋喃并吡啶酮 |
| WO2009158315A1 (en) * | 2008-06-25 | 2009-12-30 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| DK2455381T5 (en) | 2009-07-17 | 2015-02-09 | Japan Tobacco Inc | Triazolopyridinforbindelse and its effect as an inhibitor of prolyl hydroxylase and induce erythropoietin production by |
| EP2467361A1 (de) * | 2009-08-20 | 2012-06-27 | Vifor (International) Ag | Neue chinolin-hepcidin-antagonisten |
| EP2670750B1 (en) | 2011-02-02 | 2016-09-14 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor |
| WO2013043621A1 (en) | 2011-09-23 | 2013-03-28 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| EP2810944A1 (en) * | 2012-01-31 | 2014-12-10 | Toyama Chemical Co., Ltd. | Heterocyclic compound having anti-hiv activity |
-
2013
- 2013-12-23 AU AU2013368843A patent/AU2013368843B2/en active Active
- 2013-12-23 US US14/652,024 patent/US9394300B2/en active Active
- 2013-12-23 BR BR112015014222-2A patent/BR112015014222B1/pt active IP Right Grant
- 2013-12-23 SG SG11201504458XA patent/SG11201504458XA/en unknown
- 2013-12-23 CA CA2894636A patent/CA2894636C/en active Active
- 2013-12-23 ES ES13828997.0T patent/ES2660288T3/es active Active
- 2013-12-23 TW TW102147766A patent/TWI598339B/zh active
- 2013-12-23 EA EA201591195A patent/EA028402B1/ru not_active IP Right Cessation
- 2013-12-23 AP AP2015008502A patent/AP2015008502A0/xx unknown
- 2013-12-23 CN CN201380067856.4A patent/CN104903295B/zh active Active
- 2013-12-23 NZ NZ708605A patent/NZ708605A/en unknown
- 2013-12-23 UA UAA201506784A patent/UA117122C2/uk unknown
- 2013-12-23 JO JOP/2013/0383A patent/JO3781B1/ar active
- 2013-12-23 KR KR1020157016080A patent/KR101733901B1/ko active Active
- 2013-12-23 WO PCT/IN2013/000796 patent/WO2014102818A1/en not_active Ceased
- 2013-12-23 TR TR2018/02305T patent/TR201802305T4/tr unknown
- 2013-12-23 MX MX2015008233A patent/MX373392B/es active IP Right Grant
- 2013-12-23 EP EP13828997.0A patent/EP2935221B1/en active Active
- 2013-12-23 MY MYPI2015001457A patent/MY175854A/en unknown
- 2013-12-23 JP JP2015548889A patent/JP6026013B2/ja active Active
- 2013-12-27 AR ARP130105055A patent/AR094300A1/es active IP Right Grant
-
2015
- 2015-05-27 ZA ZA2015/03814A patent/ZA201503814B/en unknown
- 2015-05-29 MA MA38138A patent/MA38138A1/fr unknown
- 2015-06-01 IL IL239109A patent/IL239109B/en active IP Right Grant
- 2015-06-22 CL CL2015001802A patent/CL2015001802A1/es unknown
- 2015-06-23 PH PH12015501452A patent/PH12015501452B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015001802A1 (es) | Compuestos derivados de quinolonas; composicion farmaceutica; y uso para el tratamiento de enfermedaddes mediadas por la inhibicion de hif polilhidrolasa, tal como infarto al miocardio, accidente cerebrovascular, anemia, entre otros | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| CO7071129A2 (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CO6960541A2 (es) | Nueva composición farmacéutica resistente al abuso para el tratamiento de la dependencia de opioides | |
| CL2014001855A1 (es) | Compuestos derivados de imidazopirrolidinona o sus sales, formas cristalinas; composicion farmaceutica que los comprende; y su uso para el tratamiento de un trastorno o enfermedad mediada por la actividad de mdm2 y/o mdm4 tales como enfermedades proliferativas, especialmente cancer. | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
| CL2015001724A1 (es) | Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros. | |
| CL2014002334A1 (es) | Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras. | |
| CL2014001858A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer. | |
| LT2916860T (lt) | Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą | |
| CL2015000482A1 (es) | Compuestos derivado de 6-aminoacido-heteriarildihidropirimidinas; proceso de obtención; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la infección por el virus de la hepatitis b | |
| CL2014001065A1 (es) | Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer. | |
| CL2014002919A1 (es) | Compuestos derivados de 1h-indol-4-il-metil-(heterociclo benzofusionado); composicion y combinacion farmaceutica; y uso en el tratamiento de un trastorno mediado por la activacion del complemento o la ruta alternativa del mismo. | |
| CL2014002301A1 (es) | Compuestos derivados de pirimidin piridinas sustituidas, inhibidores de serina/treonina cinasas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento de una enfermedad hiperproliferativa tal como melanoma, cancer, leucemias y una enfermedad inflamatoria como artritis y reumatismo entre otras. | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| CL2015001014A1 (es) | Composicion de silicato de zirconio microporoso, util para el tratamiento de la hipercalemia | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| EP2845602A4 (en) | CYCLOSPORINE-CONTAINING NON-REFRESHING OPHTHALMIC NANOEMULSION COMPOSITION | |
| CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| CL2014001772A1 (es) | Compuestos derivados de (furano/pirano)-[2,3, b]piridin-amida, antagonistas del receptor p2x7; composicion farmaceutica; y su uso para el tratamiento del dolor, enfermedades neurodegenerativas, neuroinflamatorias, entre otras. | |
| LT2939665T (lt) | Farmacinė kompozicija, skirta živ infekcijų gydymui |